Loading
A phase 2 trial of Iopofosine I 131 single dose in waldenström macroglobulinaemia, multiple myeloma, chronic lymphocytic leukaemia, non-Hodgkin lymphoma, mantle cell lymphoma and diffuse large B-cell lymphoma, run by Cellectar Biosciences, Inc., active and no longer recruiting.
Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom is a phase 2 interventional study registered as NCT02952508 by Cellectar Biosciences, Inc., with 120 participants enrolled, started 2017-07-26 and due to reach its primary completion in 2026-06-22. Interventions recorded: Iopofosine I 131 single dose, Iopofosine I 131 multiple dose and Iopofosine I 131 fractionated dose.
Shares Chronic lymphocytic leukaemia, Multiple myeloma, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Waldenström macroglobulinaemia, Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Diffuse large B-cell lymphoma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Multiple myeloma, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Mantle cell lymphoma, Chronic lymphocytic leukaemia, Diffuse large B-cell lymphoma and the tag pipeline.